sertraline hydrochloride hydrate | 346607-50-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: sertraline hydrochloride hydrate
• 英文别名: (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine;hydrate;hydrochloride
• CAS: 346607-50-9
• 化学式: C₁₇H₁₇Cl₂N*ClH*H₂O
• 分子量: 360.711
• InChiKey: JRBDQWABTPEHOJ-RSAMZESZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.78
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  13
• 氢给体数：
  3
• 氢受体数：
  2

文献信息

• Sertraline hydrochloride form II and methods for the preparation thereof
  申请人：——

  公开号：US20020183555A1

  公开（公告）日：2002-12-05

  The present invention is directed to Form II of sertraline hydrochloride and novel methods for its preparation. According to the present invention, sertraline hydrochloride Form II may be produced directly form sertraline base or sertraline mandelate. It may also be produced from sertraline hydrochloride solvate and hydrate forms, and crystallized from new solvent systems. Pharmaceutical compositions containing sertraline hydrochloride Form II and methods of treatment using such pharmaceutical compositions are also disclosed.

  本发明涉及盐酸舍曲林的II型形式，以及其制备的新方法。根据本发明，盐酸舍曲林的II型形式可以直接从舍曲林碱或舍曲林曼德酸盐制备。它还可以从盐酸舍曲林的溶剂结晶态和水合态制备，并从新的溶剂体系结晶。还披露了含有盐酸舍曲林II型形式的药物组合物以及使用这种药物组合物进行治疗的方法。
• [EN] SERTRALINE HYDROCHLORIDE POLYMORPHS<br/>[FR] POLYMORPHES DE CHLORHYDRATE DE SERTRALINE
  申请人：TEVA PHARMA

  公开号：WO2000032551A1

  公开（公告）日：2000-06-08

  The present invention is directed to forms II, III, V, VI, VII, VIII, IX and X of sertraline hydrochloride and novel methods for their preparation. According to the present invention, sertraline hydrochloride polymorph II may be produced by slurrying sertraline hydrochloride polymorph VI in aprotic organic solvent. Sertraline hydrochloride polymorphic form III may be produced by heating sertraline hydrochloride polymorphs V and VI. Sertraline hydrochloride forms V and VI may be produced from either sertraline hydrochloride or sertraline base by crystallization. Sertraline hydrochloride Form VII may be produced by suspending sertraline chloride polymorph V in water, followed by filtration. Sertraline hydrochloride Forms VIII and IX may be produced by suspending sertraline base in water followed by acidification and filtration. Sertraline hydrochloride Form X and be produced by suspending sertraline hydrochloride in benzyl alcohol with heating, followed by filtration.

  本发明涉及盐酸舍曲林的II、III、V、VI、VII、VIII、IX和X形态，以及它们的新制备方法。根据本发明，可以通过在无极性有机溶剂中搅拌盐酸舍曲林的VI形态来制备盐酸舍曲林的多晶II形态。可以通过加热盐酸舍曲林的V和VI形态来制备盐酸舍曲林的III形态。盐酸舍曲林的V和VI形态可以通过从盐酸舍曲林或舍曲林碱晶体中结晶得到。可以通过在水中悬浮盐酸舍曲林的V形态，然后过滤来制备盐酸舍曲林的VII形态。可以通过在水中悬浮舍曲林碱，然后酸化和过滤来制备盐酸舍曲林的VIII和IX形态。可以通过在苯甲醇中加热悬浮盐酸舍曲林，然后过滤来制备盐酸舍曲林的X形态。
• Sertraline hydrochloride polymorphs
  申请人：——

  公开号：US20040220280A1

  公开（公告）日：2004-11-04

  The present invention is directed to forms II, III, V, VI, VII, VIII, IX and X of sertraline hydrochloride and novel methods for their preparation. According to the present invention, sertraline hydrochloride polymorph II may be produced by slurrying sertraline hydrochloride polymorph VI in aprotic organic solvent. Sertraline hydrochloride polymorphic form III may be produced by heating sertraline hydrochloride polymorphs V and VI. Sertraline hydrochloride forms V and VI may be produced from either sertraline hydrochloride or sertraline base by crystallization. Sertraline hydrochloride Form VII may be produced by suspending sertraline chloride polymorph V in water, followed by filtration. Sertraline hydrochloride Forms VIII and IX may be produced by suspending sertraline base in water followed by acidification and filtration. Sertraline hydrochloride Form X may be produced by suspending sertraline hydrochloride in benzyl alcohol with heating, followed by filtration.

  本发明涉及盐酸舍曲林的II、III、V、VI、VII、VIII、IX和X形态，以及其制备的新方法。根据本发明，可以通过在无极性有机溶剂中悬浮盐酸舍曲林的VI形态来制备盐酸舍曲林的II多晶形态。可以通过加热盐酸舍曲林的V和VI多晶形态来制备盐酸舍曲林的III多晶形态。盐酸舍曲林的V和VI形态可以通过从盐酸舍曲林或舍曲林碱晶体中结晶得到。可以通过在水中悬浮盐酸舍曲林的V多晶形态，然后过滤来制备盐酸舍曲林的VII多晶形态。可以通过在水中悬浮舍曲林碱，然后酸化和过滤来制备盐酸舍曲林的VIII和IX多晶形态。可以通过在苯甲醇中加热悬浮盐酸舍曲林，然后过滤来制备盐酸舍曲林的X多晶形态。
• Polymorphic forms of sertraline hydrochloride
  申请人：——

  公开号：US20040132828A1

  公开（公告）日：2004-07-08

  A crystalline form of sertraline hydrochloride was found, referred to hereinafter as polymorphic form CSC2 having a dissolution rate which surprisingly will increase rate of absorption of a drug. Furthermore, different crystalline forms of sertraline hydrochloride alcohol solvates, crystalline forms of sertraline hydrochloride hydrates, referred to hereinafter as polymorphic form CSC1, a process for the preparation of the amorphous form of sertraline hydrochloride, and different processes for the preparation of polymorphic forms I, II, V, and T1 are disclosed.

  发现了一种晶体形式的盐酸舍曲林，下文称为多晶形态CSC2，具有出乎意料的溶解速率，能够增加药物的吸收速度。此外，还公开了不同的晶体形式的盐酸舍曲林醇溶剂化物、盐酸舍曲林水合物的多晶形态CSC1，以及制备舍曲林盐酸无定形形态的方法，以及制备多晶形态I、II、V和T1的不同方法。
• EP1133459A4
  申请人：——

  公开号：EP1133459A4

  公开（公告）日：2004-09-29